No. It’s not all nonsense, but some of it definitely is. This article from Diana Kwon does a good job of discussing some of the industry’s challenges (with a quote from yours truly).
Chris Aimone and were fortunate to be given the opportunity to present from the Digital Health Summit stage at CES 2019. Here’s what we said.
I really enjoyed giving this talk, on neurotechnology as a career and how to move from academic science into business, at BrainHack Toronto 2018.
In putting together the article above, Christina Farr was gracious enough to listen to my theory about Apple’s not-so-secret plan that explains why there’s suddenly an ECG in the Apple Watch 4. What surprised me the most is that everyone focused on it as an ECG, including all of the tech and digital health press,
We will soon reach a milestone: sometime in the not too distant future, a consumer neurotechnology will sell millions of units. Not long after, a neurotechnology will sell millions of units per year, and so on. This is NOT fiction. This is where we’re going right now.
(These are my remarks to the neurotechnology workshop of the OECD Working Group on Emerging Technologies.)
As part of the Ontario360 30-on-30 initiative organized by Sean Speer at the Munk School of Public Policy, creative policy suggestions (proposed as non-partisan transition briefings for Ontario’s new government, just before the election) were solicited on how to solve some of the province’s toughest challenges. Here’s my contribution on economic development, R&D, and innovation.
A few weeks ago, Neil Desai and I took issue with the feel-good narrative about growth in Canadian tech and innovation in The Globe and Mail. You can read our piece here.
I’ve decided to start sharing some thoughts. Stay tuned for more.